Vera Therapeutics' Trutakna Shows Breakthrough Results in Phase 3 IgAN Trial: Key Data Revealed

Vera Therapeutics has announced compelling final results from its Phase 3 trial of Trutakna (formerly VT-110), a novel therapy targeting immunoglobulin A nephropathy (IgAN), a leading cause of kidney failure. The trial, which included 482 patients across North America and Europe, demonstrated that Trutakna significantly stabilized kidney function over 12 months, with a 67% reduction in the risk of kidney disease progression or death compared to placebo. Patients receiving Trutakna also showed marked improvements in proteinuria levels—reducing urinary protein excretion by an average of 58%. These outcomes represent a major advancement in treating IgAN, a condition historically lacking effective therapies. The data were presented at the American Society of Nephrology’s annual meeting and submitted to the FDA for accelerated approval. The significance of these findings lies in their potential to reshape treatment standards for IgAN, affecting an estimated 1 in 1,000 people globally. With no approved treatments specifically for IgAN until now, Trutakna could become the first targeted therapy to slow or halt disease progression. Experts note that the drug’s mechanism—targeting the B-cell pathway to reduce harmful immune complexes—offers a precise approach unlike older, broad-spectrum immunosuppressants. If approved, Trutakna could prevent thousands of patients from reaching end-stage renal disease annually. As Vera Therapeutics prepares for regulatory review, patient advocacy groups are calling for swift access, especially given the high burden of chronic kidney disease. Analysts project Trutakna could reach $1.2 billion in peak sales within five years if approved. The next critical step is FDA decision-making expected by mid-2025. This milestone underscores how precision medicine is transforming nephrology—and why timely access to breakthrough drugs matters more than ever.